Group 1 - XuanZhu Bio-B (02575) saw a significant increase in stock price, rising over 9% to reach a new high of 71.6 HKD, with a current price of 69.7 HKD and a trading volume of 38.59 million HKD [1] - The company announced that its product NG-350A, licensed from clinical-stage oncology company Akamis, received Fast Track designation from the FDA for the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) [1] - XuanZhu Bio holds exclusive rights for the development, production, and commercialization of NG-350A in the Greater China region [1] Group 2 - From October 30 to November 3, the National Healthcare Security Administration (NHSA) is conducting negotiations for the 2025 National Basic Medical Insurance Drug List, which includes price negotiations for innovative drugs [1] - XuanZhu Bio's drug Pyrocil has successfully passed the preliminary review for inclusion in the national medical insurance list, making its final inclusion critical for the company [1]
港股异动 | 轩竹生物-B(02575)尾盘涨超9%创上市新高 NG-350A此前获授美国FD...